Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Fagron NV is a publicly traded multinational company governed by Belgian law, specializing in pharmaceutical compounding to enable personalized medicine for hospitals, pharmacies, clinics, and patients worldwide. Headquartered in Rotterdam, Netherlands, with its registered office in Waregem, Belgium, it supplies essential raw materials, semi-finished products, vehicles, packaging, laboratory equipment, and compounding software under its own brand. The company offers sterile and non-sterile compounding services, outsourcing solutions, and pharmacogenomic testing like TrichoTest to support tailored therapies. Active in over 35 countries across Europe, North America, Latin America, Asia-Pacific, Africa, and beyond, Fagron NV serves more than 150,000 customers through operational excellence and strategic acquisitions, such as Amber Compounding Pharmacy in Singapore and Malaysia, and Vepakum in Brazil. Founded in 1990 by Ger van Jeveren, it evolved from raw materials distribution to a global leader, employing nearly 4,000 people and driving innovation in personalized treatments to address drug shortages, enhance patient outcomes, and meet individual healthcare needs.
€24.05
€0.10 (-0.41%)
EOD Jun 23, 2026 · Twelve Data
15.49% operating margin is respectable but not wide. ROIC at 11.98%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 9.2%, steady but not accelerating.
Even for strong businesses, today's 19x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
19.4x earnings, 14.1x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€952M
▲ +9.2% YoY
Net Income (TTM)
€92M
▲ +13.0% YoY
Op. Margin
15.49%
ROIC
11.98%
▼ -0.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€125M
▲ +80.4% YoY
Op. Cash Flow (TTM)
€136M
▲ +39.7% YoY
Net Debt
€283M
Cash & Equiv.
€185M
3Y CAGR: +11.7%
3Y CAGR: +11.1%
Continue Research
At a P/E of 19.4 and a price-to-free-cash-flow of 14.1, Fagron NV (FAGR.XBRU) trades below a two-stage DCF intrinsic value of about €67.22 per share, so at €24.05 the stock looks undervalued (179.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Fagron NV scores 75/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.5%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €67.22 per share for FAGR.XBRU, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €50.42. At today's €24.05, that puts the stock about 179.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Fagron NV scores 75 out of 100 on Intrinsiqq's quality score, passing 6 of 8 checks, which makes it a solid business on these measures. Recent fundamentals include a 15.5% operating margin and a 12.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
Yes, Fagron NV pays a regular dividend of about €0.36 per share per year (typically in quarterly installments), a yield of roughly 1.5% at the current price. That is a payout ratio of about 28.4% of earnings, so the dividend is amply covered by earnings. Fagron NV has grown the dividend at roughly 18.9% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For FAGR.XBRU's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. FAGR.XBRU currently trades below its estimated intrinsic value and scores 75/100 on quality (solid). It also yields about 1.5%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.